CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

back to search results

CD30 (Ki-1 Antigen) [Ber-H2]

Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: Ber-H2
Host: Mouse
Isotype: IgG1
Application: Immunohistochemistry (IHC)
Application notes: Prediluted
Conjugation Type: Unconjugated
Lightchain type: Kappa
Reactivity: Human
General notes: Localization: cytoplasm, membrane.
Buffer: citrate pH6.0
UNSPSC code: 12352203

CD30, TNF-receptor superfamily member, is a receptor for TNFSF8/CD30L. TRAF2 and TRAF5 can interact with this receptor and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and it also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. The CD30 antibody labels activated B and T cells. It has been useful in identifying Hodgkin’s lymphoma, anaplastic large cell lymphomas (ALCL) and primary cutaneous CD30+ T-cell lymphoproliferative disorders. In non-lymphoid malignancies, CD30 reactivity has been reported in embryonal carcinomas (ECs), seminomas, and hepatocellular carcinomas. (Shipping Cost: €200.00)

CD30 (Ki-1 Antigen) [Ber-H2]

CD30, TNF-receptor superfamily member, is a receptor for TNFSF8/CD30L. TRAF2 and TRAF5 can interact with this receptor and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and it also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. The CD30 antibody labels activated B and T cells. It has been useful in identifying Hodgkin’s lymphoma, anaplastic large cell lymphomas (ALCL) and primary cutaneous CD30+ T-cell lymphoproliferative disorders. In non-lymphoid malignancies, CD30 reactivity has been reported in embryonal carcinomas (ECs), seminomas, and hepatocellular carcinomas.